Amplio Pharma has reported phase 1b results for NovoBioJect, an investigational combination of low-dose methotrexate (MTX) and novobiocin being developed as a potential first-line treatment for rheumatoid arthritis (RA). In a 12-patient study, a single dose of NovoBioJect produced a 38% increase in intracellular long-chain MTX polyglutamates (MTX-PG4 and MTX-PG5) compared with MTX alone. The […]
The post Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis appeared first on Pharmafile.